Advances on systemic treatment for lung neuroendocrine neoplasms.

摘要: Lung well-to-moderately differentiated neuroendocrine tumors (also known as carcinoids) and large cell lung carcinoma (poorly tumor) are rare neoplasms, which account for less than 4% of all neoplasms. Due to their low incidence, systemic treatment is greatly influenced by therapeutic evidence derived from the more frequent gastroenteropancreatic neoplasms and/or small leading significant bias. Currently, employed therapies carcinoids, aiming at controlling tumor growth include long acting somatostatin analogues (SSAs), peptide receptor radionuclide therapy, chemotherapy molecular-targeted therapy. In this review, each those treatments presented based upon available clinical retrospective prospective studies particularly focused on role everolimus in advanced setting ongoing trials reflecting our expectations near future. addition, we critically analyse currently where appropriate chemotherapeutic regimen still a matter debate.